TLR7 and neoplasm: R848 (a TLR7/8 agonist) was loaded into dendrimers to remodel TME for effective cancer immunotherapy, effectively polarizing M2 macrophages to the M1 phenotype, increasing the maturity and activity of APCs, decreasing the amount of immunosuppressive myeloid cells, and enhancing the infiltration of tumor cytotoxic T cells to significantly stimulate the TME.279